美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

百济神州

285.30

-13.6100-4.55%

盘后：285.610.3100+0.11%18:26 EDT

成交量：28.48万

成交额：8,195.95万

市值：316.68亿

市盈率：548.23

高：293.98

开：293.37

低：284.43

收：298.91

52周最高：385.22

52周最低：196.45

股本：1.11亿

流通股本：8,557.73万

量比：1.18

换手率：0.33%

股息：- -

股息率：- -

每股收益(TTM):0.5204

每股收益(LYR):2.47

净资产收益率：7.46%

总资产收益率：3.96%

市净率：7.26

市盈率(LYR):115.51

数据加载中...

总览公司新闻资讯公告

百济神州(06160)根据股份计划发行74.13万股

单品全球营收280亿，百济神州迎来首次年度盈利

科创板成长层首批“退层”企业出炉！百济神州、寒武纪等在列

东方财富网

百济神州(06160)：2018 员工购股计划的新一轮认购期自3月2日起至8月31日止

营收382亿！创新药“一哥”百济神州，全面扭亏

百济神州授出合共2.12万股美国存托股份受限制股份单位

百济神州(06160)授出合共2.12万股美国存托股份受限制股份单位

百济神州涨1.02% 股价突破300美元大关

百济神州“增长之问”：泽布替尼美国市占率登顶后，下一个五年能走多远？

动脉新医药

超130家药企亏损太惊人，318家晒2025成绩单！百济神州、特宝生物净利润首破10亿，奇正、千金……亮眼

百济神州交流纪要

调研三人行

异动解读 | 百济神州盘中大跌5.34%，港股创新药板块回调资金“利好出尽”撤离

首次全年盈利，百济神州为何股价三地齐跌？

中国新闻网

异动解读 | 百济神州盘前大跌5.20%，港股创新药板块回调资金“利好出尽”撤离

港股创新药大幅回调，百济神州领跌；沪鸽三度冲刺港交所，上市之路为何如此坎坷？|掘金创新药

每日经济新闻

交银国际：百济神州(06160)上季产品销售强势维持“买入”评级

百济神州业绩亮丽：砸40%营收做研发、狂赚逾14亿

Ofweek光电信息网

国金证券：维持百济神州(06160)“买入”评级早研管线步入收获期

【私募调研记录】景林资产调研百济神州

业绩快报密集披露电子及医药生物行业“领跑”

中国经济新闻网

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/ONC/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":285.3,"timestamp":1773345600000,"preClose":298.91,"halted":0,"volume":284781,"hourTrading":{"tag":"盘后","latestPrice":285.61,"preClose":285.3,"latestTime":"18:26 EDT","volume":1612,"amount":459905.0508,"timestamp":1773354362768,"change":0.31,"changeRate":0.001087,"amplitude":0.001087},"delay":0,"changeRate":-0.045532099963199665,"floatShares":85577300,"shares":111000000,"eps":0.5204,"marketStatus":"盘后交易","change":-13.61,"latestTime":"03-12 18:56:50 EDT","open":293.37,"high":293.975,"low":284.43,"amount":81959524.69383,"amplitude":0.031933,"askPrice":289,"askSize":1,"bidPrice":285.6,"bidSize":10,"shortable":3,"etf":0,"ttmEps":0.5204,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1773360000000},"marketStatusCode":4,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":298.91,"preHourTrading":{"tag":"盘前","latestPrice":290.31,"preClose":298.91,"latestTime":"09:28 EDT","volume":11783,"amount":3513751.8715999997,"timestamp":1773322080071,"change":-8.6,"changeRate":-0.028771,"amplitude":0.018969},"postHourTrading":{"tag":"盘后","latestPrice":285.61,"preClose":285.3,"latestTime":"18:26 EDT","volume":1612,"amount":459905.0508,"timestamp":1773354362768,"change":0.31,"changeRate":0.001087,"amplitude":0.001087},"volumeRatio":1.176161,"impliedVol":0.4394,"impliedVolPercentile":0.4622},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":85577300,"roa":"3.96%","roe":"7.46%","lyrEps":2.469999,"volumeRatio":1.176161,"shares":111000000,"dividePrice":0,"high":293.975,"amplitude":0.031933,"preClose":298.91,"low":284.43,"week52Low":196.45,"pbRate":"7.26","psRate":"5.93","week52High":385.22,"institutionHeld":0,"latestPrice":285.3,"committee":0.818182,"eps":0.5204,"divideRate":0,"volume":284781,"delay":0,"ttmEps":0.5204,"open":293.37,"prevYearClose":303.81,"prevWeekClose":301.12,"prevMonthClose":316.99,"prevQuarterClose":303.81,"fiveDayClose":292.94,"twentyDayClose":351.27,"sixtyDayClose":319.06},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-02-26","symbol":"ONC","fiscalQuarterEnding":"2025/12","expectedEps":1.6,"name":null,"time":"盘前","type":"earning","dateTimestamp":1772082000000,"reportTimeType":"pre","actualEps":0.58},{"market":"US","date":"2025-11-06","symbol":"ONC","fiscalQuarterEnding":"2025/09","expectedEps":0.72,"name":null,"time":"盘后","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":1.09},{"date":"2025-08-30","symbol":"ONC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756540800000,"name":null,"time":"盘前","dateTimestamp":1756526400000,"actualEps":null},{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"盘前","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2917,"buy":0.6667,"hold":0,"sell":0.0417,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":24,"updateTime":1768017600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2026-03-11","current":548.232129,"percent":0.82774,"low":-217.585346,"twenty":-81.162588,"median":-39.111643,"eighty":-19.655586,"high":609.337035,"avg":34.646119,"sd":235.639937,"marketCap":33880901704},"quantilePoints":[{"date":"2024-05-31","current":-19.860847,"twenty":-20.46703,"median":-20.284421,"eighty":-20.042184,"marketCap":15579384952},{"date":"2024-06-07","current":-20.864085,"twenty":-20.930269,"median":-20.558927,"eighty":-20.042184,"marketCap":16366351618},{"date":"2024-06-14","current":-21.694058,"twenty":-21.409839,"median":-20.844737,"eighty":-20.30869,"marketCap":17017405001},{"date":"2024-06-21","current":-20.966373,"twenty":-21.331475,"median":-20.876952,"eighty":-20.46703,"marketCap":16446589390},{"date":"2024-06-28","current":-19.234246,"twenty":-21.331475,"median":-20.825389,"eighty":-19.981739,"marketCap":15087861974},{"date":"2024-07-05","current":-19.83401,"twenty":-21.208618,"median":-20.693442,"eighty":-19.760805,"marketCap":15558333278},{"date":"2024-07-12","current":-20.525989,"twenty":-21.135228,"median":-20.465877,"eighty":-19.641074,"marketCap":16101139655},{"date":"2024-07-19","current":-20.872652,"twenty":-21.016911,"median":-20.525989,"eighty":-19.707798,"marketCap":16373071895},{"date":"2024-07-26","current":-21.924783,"twenty":-21.374239,"median":-20.660298,"eighty":-19.760805,"marketCap":17198391533},{"date":"2024-08-02","current":-22.081827,"twenty":-21.704901,"median":-20.777003,"eighty":-19.839377,"marketCap":17321581561},{"date":"2024-08-09","current":-37.033118,"twenty":-22.009534,"median":-20.868368,"eighty":-19.874904,"marketCap":19394058972},{"date":"2024-08-16","current":-39.443432,"twenty":-22.36867,"median":-20.966373,"eighty":-19.937065,"marketCap":20656328240},{"date":"2024-08-23","current":-39.274234,"twenty":-33.284244,"median":-21.171036,"eighty":-20.00126,"marketCap":20567720015},{"date":"2024-08-30","current":-38.860864,"twenty":-37.912544,"median":-21.248991,"eighty":-20.190606,"marketCap":20351240040},{"date":"2024-09-06","current":-38.812817,"twenty":-38.506257,"median":-21.456019,"eighty":-20.300725,"marketCap":20326078245},{"date":"2024-09-13","current":-40.29759,"twenty":-38.865563,"median":-21.710093,"eighty":-20.355918,"marketCap":21103646159},{"date":"2024-09-20","current":-41.008162,"twenty":-39.353261,"median":-21.954664,"eighty":-20.405766,"marketCap":21475769498},{"date":"2024-09-27","current":-44.343793,"twenty":-39.883427,"median":-22.072098,"eighty":-20.507104,"marketCap":23222622772},{"date":"2024-10-04","current":-49.961787,"twenty":-40.117185,"median":-22.410559,"eighty":-20.525989,"marketCap":26164738255},{"date":"2024-10-11","current":-47.875901,"twenty":-40.317892,"median":-22.855632,"eighty":-20.558927,"marketCap":25072369873},{"date":"2024-10-18","current":-44.402313,"twenty":-41.008162,"median":-37.033118,"eighty":-20.627155,"marketCap":23253269086},{"date":"2024-10-25","current":-43.1532,"twenty":-43.068033,"median":-37.882149,"eighty":-20.693442,"marketCap":22599114920},{"date":"2024-11-01","current":-41.429716,"twenty":-43.148001,"median":-38.271158,"eighty":-20.724275,"marketCap":21696535276},{"date":"2024-11-08","current":-41.685343,"twenty":-43.068033,"median":-38.746669,"eighty":-20.777003,"marketCap":21830405481},{"date":"2024-11-15","current":-24.188369,"twenty":-42.835701,"median":-38.506257,"eighty":-20.825389,"marketCap":20104967290},{"date":"2024-11-22","current":-24.46985,"twenty":-42.494274,"median":-38.062423,"eighty":-20.864085,"marketCap":20240962418},{"date":"2024-11-29","current":-27.613239,"twenty":-42.262623,"median":-37.45966,"eighty":-20.870939,"marketCap":22851200825},{"date":"2024-12-06","current":-26.519964,"twenty":-42.078114,"median":-35.811244,"eighty":-20.886386,"marketCap":21862847938},{"date":"2024-12-13","current":-23.158686,"twenty":-41.984053,"median":-26.690447,"eighty":-20.951062,"marketCap":19077141333},{"date":"2024-12-20","current":-22.876382,"twenty":-41.961072,"median":-26.519964,"eighty":-21.016911,"marketCap":18791641889},{"date":"2024-12-27","current":-23.581122,"twenty":-41.848457,"median":-25.970587,"eighty":-21.108807,"marketCap":19365505627},{"date":"2025-01-03","current":-23.522344,"twenty":-41.738903,"median":-25.015322,"eighty":-21.169159,"marketCap":19262068568},{"date":"2025-01-10","current":-23.039426,"twenty":-41.667895,"median":-24.95255,"eighty":-21.188412,"marketCap":18831625271},{"date":"2025-01-17","current":-27.361812,"twenty":-41.564427,"median":-24.990614,"eighty":-21.226086,"marketCap":22387798297},{"date":"2025-01-24","current":-28.60727,"twenty":-41.429716,"median":-25.817461,"eighty":-21.248991,"marketCap":23666613889},{"date":"2025-01-31","current":-29.006926,"twenty":-41.129457,"median":-26.292693,"eighty":-21.405551,"marketCap":23976726670},{"date":"2025-02-07","current":-29.003485,"twenty":-41.095232,"median":-26.532547,"eighty":-21.456019,"marketCap":23849552911},{"date":"2025-02-14","current":-29.812673,"twenty":-41.008162,"median":-26.754345,"eighty":-21.694058,"marketCap":24634934161},{"date":"2025-02-21","current":-32.964646,"twenty":-40.974605,"median":-27.361812,"eighty":-21.704901,"marketCap":27250381776},{"date":"2025-02-28","current":-45.085214,"twenty":-41.025576,"median":-28.423545,"eighty":-21.711581,"marketCap":29070314911},{"date":"2025-03-07","current":-41.087466,"twenty":-41.189509,"median":-28.729221,"eighty":-21.882341,"marketCap":26492622821},{"date":"2025-03-14","current":-43.209977,"twenty":-41.608729,"median":-28.790129,"eighty":-21.948688,"marketCap":27861188167},{"date":"2025-03-21","current":-42.024306,"twenty":-41.961072,"median":-29.003485,"eighty":-22.009534,"marketCap":27096684166},{"date":"2025-03-28","current":-44.59433,"twenty":-42.028738,"median":-29.052749,"eighty":-22.054545,"marketCap":28753799426},{"date":"2025-04-04","current":-39.846019,"twenty":-42.270172,"median":-29.231496,"eighty":-22.077935,"marketCap":25692155286},{"date":"2025-04-11","current":-38.484462,"twenty":-42.209323,"median":-29.379987,"eighty":-22.177258,"marketCap":24814242135},{"date":"2025-04-17","current":-38.603,"twenty":-42.109763,"median":-29.75631,"eighty":-22.326782,"marketCap":24890673891},{"date":"2025-04-25","current":-40.929408,"twenty":-42.213935,"median":-30.85745,"eighty":-22.4234,"marketCap":26390709308},{"date":"2025-05-02","current":-42.799955,"twenty":-42.322726,"median":-33.161649,"eighty":-22.493794,"marketCap":27596811853},{"date":"2025-05-09","current":-63.824658,"twenty":-42.611855,"median":-33.528671,"eighty":-22.601969,"marketCap":25042625921},{"date":"2025-05-16","current":-62.94985,"twenty":-42.804476,"median":-34.892623,"eighty":-22.71748,"marketCap":24699380815},{"date":"2025-05-23","current":-72.041871,"twenty":-43.150081,"median":-36.84391,"eighty":-22.787779,"marketCap":28266780880},{"date":"2025-05-30","current":-74.527648,"twenty":-43.429182,"median":-37.087829,"eighty":-22.808465,"marketCap":29242115209},{"date":"2025-06-06","current":-77.688492,"twenty":-43.794804,"median":-38.030583,"eighty":-22.84042,"marketCap":30482322820},{"date":"2025-06-13","current":-89.808695,"twenty":-44.177303,"median":-38.271158,"eighty":-22.941372,"marketCap":35237878321},{"date":"2025-06-20","current":-76.439732,"twenty":-44.40516,"median":-38.484462,"eighty":-23.038971,"marketCap":29992352055},{"date":"2025-06-27","current":-76.95683,"twenty":-44.800569,"median":-38.641761,"eighty":-23.063278,"marketCap":30195243589},{"date":"2025-07-03","current":-74.11053,"twenty":-45.138397,"median":-38.836841,"eighty":-23.158686,"marketCap":29078452032},{"date":"2025-07-11","current":-76.495446,"twenty":-45.905367,"median":-39.006759,"eighty":-23.171606,"marketCap":30014212230},{"date":"2025-07-18","current":-87.653233,"twenty":-47.435675,"median":-39.313748,"eighty":-23.176246,"marketCap":34392148550},{"date":"2025-07-25","current":-89.648478,"twenty":-48.541013,"median":-39.640999,"eighty":-23.189441,"marketCap":35175014575},{"date":"2025-08-01","current":-91.060669,"twenty":-60.626235,"median":-39.865155,"eighty":-23.250607,"marketCap":35729110635},{"date":"2025-08-08","current":-184.757225,"twenty":-63.824658,"median":-40.051934,"eighty":-23.50984,"marketCap":32820458238},{"date":"2025-08-15","current":-191.818248,"twenty":-64.911375,"median":-40.112152,"eighty":-23.522344,"marketCap":34074785315},{"date":"2025-08-22","current":-194.469228,"twenty":-72.041871,"median":-40.222554,"eighty":-23.535152,"marketCap":34545708113},{"date":"2025-08-29","current":-184.552827,"twenty":-72.8475,"median":-40.343171,"eighty":-23.581122,"marketCap":32784148770},{"date":"2025-09-05","current":-197.417514,"twenty":-73.864189,"median":-40.425269,"eighty":-23.723244,"marketCap":35069444682},{"date":"2025-09-12","current":-208.147892,"twenty":-74.224679,"median":-40.801852,"eighty":-23.82061,"marketCap":36975599617},{"date":"2025-09-19","current":-212.503459,"twenty":-75.66857,"median":-40.932054,"eighty":-23.865007,"marketCap":37749326897},{"date":"2025-09-26","current":-203.715512,"twenty":-76.587723,"median":-41.008162,"eighty":-23.928977,"marketCap":36188227257},{"date":"2025-10-03","current":-213.916471,"twenty":-77.910534,"median":-41.112345,"eighty":-23.950329,"marketCap":38000335866},{"date":"2025-10-10","current":-208.109485,"twenty":-81.639564,"median":-41.598105,"eighty":-24.044918,"marketCap":36968777077},{"date":"2025-10-17","current":-197.090466,"twenty":-85.2662,"median":-41.668284,"eighty":-24.084563,"marketCap":35011347487},{"date":"2025-10-24","current":-192.138725,"twenty":-87.584871,"median":-41.753651,"eighty":-24.09529,"marketCap":34131715179},{"date":"2025-10-31","current":-191.016991,"twenty":-89.061223,"median":-41.811067,"eighty":-24.120226,"marketCap":33932449287},{"date":"2025-11-07","current":-207.03708,"twenty":-89.680521,"median":-41.96845,"eighty":-24.175905,"marketCap":36778273935},{"date":"2025-11-14","current":594.631071,"twenty":-89.43801,"median":-41.811067,"eighty":-24.044918,"marketCap":40761959883},{"date":"2025-11-21","current":563.847015,"twenty":-89.201535,"median":-41.753651,"eighty":-23.82061,"marketCap":38651712910},{"date":"2025-11-28","current":549.835185,"twenty":-89.104768,"median":-41.685343,"eighty":-23.530029,"marketCap":37691201965},{"date":"2025-12-05","current":534.967794,"twenty":-89.063642,"median":-41.61723,"eighty":-23.184163,"marketCap":36672042310},{"date":"2025-12-12","current":517.921144,"twenty":-88.590694,"median":-41.129457,"eighty":-23.039198,"marketCap":35503494432},{"date":"2025-12-19","current":495.611986,"twenty":-88.19516,"median":-41.047814,"eighty":-22.787779,"marketCap":33974201659},{"date":"2025-12-26","current":503.21518,"twenty":-87.945005,"median":-40.950457,"eighty":-22.473183,"marketCap":34495400571},{"date":"2026-01-02","current":490.430192,"twenty":-87.636143,"median":-40.899758,"eighty":-22.105685,"marketCap":33618989662},{"date":"2026-01-09","current":517.162439,"twenty":-87.22937,"median":-40.570085,"eighty":-21.930759,"marketCap":35451485198},{"date":"2026-01-16","current":546.090088,"twenty":-85.828543,"median":-40.382553,"eighty":-21.503627,"marketCap":37434475537},{"date":"2026-01-23","current":546.929506,"twenty":-85.639801,"median":-40.307741,"eighty":-21.22036,"marketCap":37492017667},{"date":"2026-01-30","current":564.993144,"twenty":-85.550958,"median":-40.153659,"eighty":-20.966373,"marketCap":38730280050},{"date":"2026-02-06","current":560.150346,"twenty":-85.195011,"median":-40.102874,"eighty":-20.825389,"marketCap":38398306221},{"date":"2026-02-13","current":559.214072,"twenty":-84.275105,"median":-39.916618,"eighty":-20.627155,"marketCap":38334124614},{"date":"2026-02-20","current":572.225057,"twenty":-83.309792,"median":-39.846883,"eighty":-20.486836,"marketCap":39226027634},{"date":"2026-02-27","current":124.64483,"twenty":-82.630374,"median":-39.542215,"eighty":-20.122622,"marketCap":35764714896},{"date":"2026-03-06","current":113.265677,"twenty":-81.639564,"median":-39.274234,"eighty":-19.815709,"marketCap":32499660582},{"date":"2026-03-11","current":118.079488,"twenty":-81.162588,"median":-39.111643,"eighty":-19.655586,"marketCap":33880901704}],"updateTime":1773356210695},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2618972362","title":"百济神州(06160)根据股份计划发行74.13万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2618972362","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618972362?lang=zh_cn&edition=fundamental","pubTime":"2026-03-12 07:44","pubTimestamp":1773272679,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2026年3月11日根据股份计划发行74.13万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412861.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK1161","BK1583","LU1303224171.USD","LU1251922891.USD","BK0239","BK4585","BK1500","BK4526","LU2328871848.SGD","LU0588546209.SGD","688235","LU1770034418.SGD","ONC","LU1969619763.USD","BK4588","BK1588","06160","LU1719994722.HKD","LU0307460666.USD"],"gpt_icon":0},{"id":"2618391754","title":"单品全球营收280亿，百济神州迎来首次年度盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2618391754","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618391754?lang=zh_cn&edition=fundamental","pubTime":"2026-03-11 16:48","pubTimestamp":1773218913,"startTime":"0","endTime":"0","summary":"得益于产品收入增长和费用管理推动的经营效率提升，公司实现归母净利润14.22亿元，这也是百济神州赴美上市十年以来首次盈利。2025年全年，百济神州产品收入达377.70亿元，同比增长39.9%。2016年，百济神州成功登陆纳斯达克，后于2018年登陆港交所。数据显示，2018年-2024年七年间，百济神州累计亏损金额超过580亿元。2025年全年，百泽安全球销售额总计52.97亿元，同比增长18.6%，稳居国产PD-1销售额榜首。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1773197551496593961","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["06160","ONC","688235"],"gpt_icon":0},{"id":"2618917443","title":"科创板成长层首批“退层”企业出炉！百济神州、寒武纪等在列","url":"https://stock-news.laohu8.com/highlight/detail?id=2618917443","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618917443?lang=zh_cn&edition=fundamental","pubTime":"2026-03-11 16:40","pubTimestamp":1773218438,"startTime":"0","endTime":"0","summary":"据统计，截至3月11日，科创板全体公司均以业绩快报或预告形式完成对2025年经营情况的披露，预计将实现营业收入1.59万亿元，同比增长10.3%；净利润591亿元，同比增长28.2%。随着业绩的集中披露，科创板成长层也将迎来首批“退层”公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1345,202603113668838022.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["LU1251922891.USD","LU2476274720.SGD","LU1770034418.SGD","LU0307460666.USD","BK0239","SG9999003461.SGD","BK4585","06160","ONC","SG9999006597.SGD","SGXZ90724238.SGD","BK1500","LU2778985437.USD","LU2476274308.USD","688235","BK1161","BK4526","SG9999001051.SGD","SG9999001069.SGD","SGXZ49509284.SGD","SG9999002950.SGD","LU1719994722.HKD","LU2328871848.SGD","BK1583","BK4139","LU0588546209.SGD","SG9999001093.SGD","BK0231","BK1588","LU1969619763.USD","159982","LU1303224171.USD","SGXZ81163826.USD","688256","BK4588"],"gpt_icon":0},{"id":"2618293810","title":"百济神州(06160)：2018 员工购股计划的新一轮认购期自3月2日起至8月31日止","url":"https://stock-news.laohu8.com/highlight/detail?id=2618293810","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618293810?lang=zh_cn&edition=fundamental","pubTime":"2026-03-10 16:53","pubTimestamp":1773132798,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州 发布公告，2018 员工购股计划的新一轮认购期自2026年3月2日起至2026年8月31日止。2018员工购股计划使合资格雇员可按市价15%折让申购股份。雇员可于认购期结束后购买股份，购股资金可从其认购期内所得薪金中扣除。本公司相信，持续为本公司雇员提供通过参与2018员工购股计划获得本公司所有权权益的机会，鼓励其继续受雇于本公司，并使其利益与本公司股东的利益更紧密地保持一致，符合本公司及股东的最佳利益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412144.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0588546209.SGD","BK1583","LU1719994722.HKD","BK0239","LU1770034418.SGD","LU1251922891.USD","BK4588","LU0307460666.USD","BK1500","LU1969619763.USD","06160","BK4139","LU1303224171.USD","688235","LU2328871848.SGD","BK4526","BK4585","BK1161","BK1588","ONC"],"gpt_icon":0},{"id":"2618009613","title":"营收382亿！创新药“一哥”百济神州，全面扭亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2618009613","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618009613?lang=zh_cn&edition=fundamental","pubTime":"2026-03-09 10:37","pubTimestamp":1773023833,"startTime":"0","endTime":"0","summary":"2月26日晚，百济神州发布2025年业绩快报。然而，面对业绩全面扭亏，市场反应冷淡。财报发布后，百济神州美股两个交易日跌幅超10%。业绩快报显示，百济神州产品收入377.70亿元，同比增长39.9%，主要由百悦泽、安进授权产品及百泽安销售增长驱动。具体来看，2025年百悦泽全球销售额280.67亿元，同比增长48.8%，创历史新高；百泽安全球销售额52.97亿元，同比增长18.6%。随着适应症持续拓展，百济神州已具备头部药企竞争力。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1772409403580961090","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["06978","159992","06160","688235","ONC"],"gpt_icon":0},{"id":"2617666539","title":"百济神州授出合共2.12万股美国存托股份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2617666539","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617666539?lang=zh_cn&edition=fundamental","pubTime":"2026-03-08 10:31","pubTimestamp":1772937060,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　百济神州（06160）发布公告，于2026年3月2日，董事会薪酬委员会根据2016期权及激励计划的条款授予180名承授人合共2.12万股美国存托股份受限制股份单位。该等受限制股份单位相当于27.56万股股份，约占本公告的日公司发行股份总数的0.02%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-03-08/doc-inhqfsut4635660.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1719994722.HKD","BK4139","BK4585","LU1770034418.SGD","BK1161","LU2328871848.SGD","LU1251922891.USD","06160","BK4526","LU0588546209.SGD","BK1500","BK1588","BK4588","LU1303224171.USD","BK0239","BK1583","LU1969619763.USD","ONC","LU0307460666.USD","688235"],"gpt_icon":0},{"id":"2617068639","title":"百济神州(06160)授出合共2.12万股美国存托股份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2617068639","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617068639?lang=zh_cn&edition=fundamental","pubTime":"2026-03-06 17:20","pubTimestamp":1772788807,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2026年3月2日，董事会薪酬委员会根据2016期权及激励计划的条款授予180名承授人合共2.12万股美国存托股份受限制股份单位。该等受限制股份单位相当于27.56万股股份，约占本公告的日公司发行股份总数的0.02%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411013.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1251922891.USD","BK4585","LU0307460666.USD","06160","LU1303224171.USD","LU1770034418.SGD","ONC","BK0239","LU0588546209.SGD","BK4588","LU1969619763.USD","BK4139","BK1588","LU1719994722.HKD","LU2328871848.SGD","688235","BK1161","BK1583","BK4526","BK1500"],"gpt_icon":0},{"id":"2617566698","title":"百济神州涨1.02% 股价突破300美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2617566698","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617566698?lang=zh_cn&edition=fundamental","pubTime":"2026-03-05 03:48","pubTimestamp":1772653689,"startTime":"0","endTime":"0","summary":"北京时间2026年03月05日03时48分，百济神州股票出现波动，股价大幅上涨1.02%。百济神州股票所在的生物技术行业中，整体涨幅为2.14%。百济神州公司简介：百济神州于2010年在北京成立，2018年在香港交易所上市，是一家全球销售的商业阶段生物技术公司。百济神州有自己的团队进行全球临床试验。截至2024年，其核心药物是百悦泽，一种治疗各种血癌的小分子药物，占百济神州收入的60%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305034809a6a3463a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305034809a6a3463a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","ONC","BK4588","BK4585","BK4139"],"gpt_icon":0},{"id":"2617661566","title":"百济神州“增长之问”：泽布替尼美国市占率登顶后，下一个五年能走多远？","url":"https://stock-news.laohu8.com/highlight/detail?id=2617661566","media":"动脉新医药","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617661566?lang=zh_cn&edition=fundamental","pubTime":"2026-03-04 17:33","pubTimestamp":1772616836,"startTime":"0","endTime":"0","summary":"百济神州方面指出。这种“增量不减”的态势，离不开泽布替尼全球化布局的深化。其中2025年Q4，泽布替尼的中国地区增速有所下滑，销售额8600万美元，环比下降6.87%，欧洲地区销售额1.67亿美元，环比增长2.45%。2025年Q3，泽布替尼的美国市场占有率达到33.8%，超过伊布替尼成为第一名，全球市场占有率在2025年Q4突破30%。百济神州方面表示。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603041812149542f65c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603041812149542f65c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","BK4588","ONC","BK4139","BK4585"],"gpt_icon":0},{"id":"2616580089","title":"超130家药企亏损太惊人，318家晒2025成绩单！百济神州、特宝生物净利润首破10亿，奇正、千金……亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2616580089","media":"米内网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616580089?lang=zh_cn&edition=fundamental","pubTime":"2026-03-04 16:32","pubTimestamp":1772613166,"startTime":"0","endTime":"0","summary":"截至目前，医药企业已有318家披露成绩单，其中近130家是业绩快报，华润三九、奇正藏药、千金药业等业绩双涨。此外，有超过130家亏损，智飞生物首亏超过100亿元。17家净利润超10亿，华润三九、奇正、千金……其中，药明康德以191.51亿元领跑，三生国健、艾力斯首次晋身20亿元梯队，百济神州、特宝生物首次突破10亿元大关。从亏损金额来看，1亿元及以上占比超6成，智飞生物亏损最多，超过100亿元，也是公司上市以来首亏。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304163930a44a75e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304163930a44a75e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","06160"],"gpt_icon":0},{"id":"2616580291","title":"百济神州 交流纪要","url":"https://stock-news.laohu8.com/highlight/detail?id=2616580291","media":"调研三人行","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616580291?lang=zh_cn&edition=fundamental","pubTime":"2026-03-04 15:13","pubTimestamp":1772608398,"startTime":"0","endTime":"0","summary":"百悦泽已迅速成为全球领先的BTK抑制剂。我们相信,百济神州是唯一一家在CLL领域产品组合和研发管线中拥有多款基石性产品的公司。目前固定疗程方案的风险收益特征无法证明有必要放弃已确立的BTK抑制剂持续治疗。目前百悦泽占据了BTK抑制剂持续治疗市场约一半的份额,百济神州将能够凭借ZS进入目前我们尚未涉足的另一半市场。百悦泽全球收入总计11亿美元,同比增长38%,各地区业绩均表现强劲。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603041532469542eebe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603041532469542eebe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1251922891.USD","LU1770034418.SGD","BK1161","ONC","LU1719994722.HKD","BK1588","LU0307460666.USD","LU1969619763.USD","BK1583","LU2328871848.SGD","LU1303224171.USD","06160","LU0588546209.SGD","BK1500"],"gpt_icon":0},{"id":"1146097023","title":"异动解读 | 百济神州盘中大跌5.34%，港股创新药板块回调资金“利好出尽”撤离","url":"https://stock-news.laohu8.com/highlight/detail?id=1146097023","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146097023?lang=zh_cn&edition=fundamental","pubTime":"2026-03-03 22:53","pubTimestamp":1772549595,"startTime":"0","endTime":"0","summary":"百济神州（ONC）今日盘中股价大跌5.34%，引起了市场的广泛关注。消息面上，此次下跌与港股创新药板块整体大幅回调有关，百济神州在板块中领跌。尽管公司此前发布了强劲的2025年业绩，实现营业总收入同比增长40.4%并成功扭亏为盈，但部分资金选择“利好出尽”式撤离，这是A股和港股市场常见的博弈行为。同时，市场对创新药企的定价逻辑正在发生根本性转变，从单纯看重管线储备转向研发能力、商业化能力与合规能力的综合考量。资金面上，外资持续流出港股医药板块，南向资金转向科技、高股息板块，港股创新药ETF近期出现净赎回，资金获利了结情绪集中释放，共同导致了股价的短期承压。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ONC"],"gpt_icon":0},{"id":"2616297723","title":"首次全年盈利，百济神州为何股价三地齐跌？","url":"https://stock-news.laohu8.com/highlight/detail?id=2616297723","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616297723?lang=zh_cn&edition=fundamental","pubTime":"2026-03-03 22:49","pubTimestamp":1772549340,"startTime":"0","endTime":"0","summary":"中新网北京3月3日电(记者赵方园)一度被冠以“烧钱一哥”的A股创新药龙头百济神州，终于在2025年迎来了历史性转折。近期，百济神州发布2025年度业绩快报，报告期内实现营业总收入382.05亿元，同比增长40.4%；归属于上市公司股东的净利润14.22亿元。而在2024年同期，公司亏损49.78亿元。这是百济神州成立十六年以来首次实现全年盈利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603033660707240.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603033660707240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1719994722.HKD","688235","LU1770034418.SGD","BK1583","LU1303224171.USD","BK4526","BK4585","LU1251922891.USD","BK1500","BK4588","ONC","LU0588546209.SGD","BK1161","LU2328871848.SGD","BK0239","LU1969619763.USD","LU0307460666.USD","BK4139","BK1588","06160"],"gpt_icon":0},{"id":"1197802256","title":"异动解读 | 百济神州盘前大跌5.20%，港股创新药板块回调资金“利好出尽”撤离","url":"https://stock-news.laohu8.com/highlight/detail?id=1197802256","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197802256?lang=zh_cn&edition=fundamental","pubTime":"2026-03-03 22:02","pubTimestamp":1772546577,"startTime":"0","endTime":"0","summary":"百济神州（ONC）今日盘前股价大跌5.20%，引起了市场的广泛关注。消息面上，此次下跌与港股创新药板块整体大幅回调有关，百济神州在板块中领跌。尽管公司此前发布了强劲的2025年业绩，但部分资金选择“利好出尽”式撤离，这是A股和港股市场常见的博弈行为。同时，市场对创新药企的定价逻辑正在发生根本性转变，从单纯看重管线储备转向研发能力、商业化能力与合规能力的综合考量。百济神州2025年业绩显示，公司实现营业总收入同比增长40.4%，并成功扭亏为盈。然而，在财报公布后，市场资金流向的变化和板块情绪的调整，共同导致了股价的短期承压。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ONC"],"gpt_icon":0},{"id":"2616253133","title":"港股创新药大幅回调，百济神州领跌；沪鸽三度冲刺港交所，上市之路为何如此坎坷？|掘金创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2616253133","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616253133?lang=zh_cn&edition=fundamental","pubTime":"2026-03-03 21:43","pubTimestamp":1772545383,"startTime":"0","endTime":"0","summary":"\"\"资本眼一周行情上周（2月24日至2月27日）医药生物指数下跌0.34%，跑输上证指数2.32个百分点。创新药（BK1106）周内上涨0.43%；恒生医疗保健业指数（HSCICH）周内下跌4.95%；港股创新药ETF（513120）周内下跌4.05%。一周点评港股创新药大幅回调，百济神州领跌上周医药生物板块呈AH股显著分化、个股两极格局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603033660664083.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603033660664083.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1969619763.USD","BK4588","LU1719994722.HKD","BK1588","688235","VXUS","LU1251922891.USD","159992","BK1161","BK1500","LU0307460666.USD","LU0588546209.SGD","BK4139","LU2328871848.SGD","BK1574","06160","LU1303224171.USD","06978","BK4526","LU1770034418.SGD","BK0239","BK4585","BK1583","VT","ONC"],"gpt_icon":0},{"id":"2616316707","title":"交银国际：百济神州(06160)上季产品销售强势 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2616316707","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616316707?lang=zh_cn&edition=fundamental","pubTime":"2026-03-03 15:09","pubTimestamp":1772521742,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研报称，百济神州去年第四季泽布替尼销售额11亿美元(下同)，同比及按季分别升38%及10%，美国销售额8.45亿，同比及按季分别升37%及14%。在1LCLL患者中，泽布在BTK品类中的份额约占一半、在所有治疗药物中约占四分之一。公司指引2026年收入62亿至64亿，GAAP经营费用47亿至49亿元，毛利率在80%区间的高位，non-GAAP净利润14亿至15亿元，维持“买入”评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409396.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ONC","06160","688235"],"gpt_icon":0},{"id":"2616318402","title":"百济神州业绩亮丽：砸40%营收做研发、狂赚逾14亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2616318402","media":"Ofweek光电信息网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616318402?lang=zh_cn&edition=fundamental","pubTime":"2026-03-03 10:37","pubTimestamp":1772505420,"startTime":"0","endTime":"0","summary":"2025年，百济神州营业总收入站上382.05亿元的新台阶，同比增长40.4%，归母净利润达到14.22亿元，2024年亏损49.78亿元。2025年能够跨过盈亏平衡线，离不开百济神州砸钱做研发，2022年至2024年公司研发费用均超过100亿元。到了2025年研发投入持续增加，百济神州2025年全年研发费用达21.46亿美元，同比增长10%，占同期营业收入比例约为40%。2月26日晚，百济神州发布了2026年业绩预测，公司预测2026年营业收入将介于436亿元至450亿元之间，较2025年营业收入的增速在14.12%与17.79%之间。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303104312a44472d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303104312a44472d9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","06160"],"gpt_icon":0},{"id":"2616783391","title":"国金证券：维持百济神州(06160)“买入”评级 早研管线步入收获期","url":"https://stock-news.laohu8.com/highlight/detail?id=2616783391","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616783391?lang=zh_cn&edition=fundamental","pubTime":"2026-03-03 10:36","pubTimestamp":1772505397,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国金证券发布研报称，维持百济神州“买入”评级。公司核心产品高速放量，研发管线有望迎来密集催化。国金证券主要观点如下：业绩简评2026年2月26日公司发布2025年业绩快报，全年实现总收入53亿美元，实现GAAP净利润2.87亿美元;其中25Q4实现总收入15亿美元，实现GAAP净利润6650万美元。风险提示商业化进展不及预期风险、市场竞争加剧风险、临床试验进展不及预期风险、产品上市审评进展不及预期风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409307.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ONC","688235","06160"],"gpt_icon":0},{"id":"2616182363","title":"【私募调研记录】景林资产调研百济神州","url":"https://stock-news.laohu8.com/highlight/detail?id=2616182363","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616182363?lang=zh_cn&edition=fundamental","pubTime":"2026-03-03 08:10","pubTimestamp":1772496652,"startTime":"0","endTime":"0","summary":"根据市场公开信息及3月2日披露的机构调研信息，知名私募景林资产近期对1家上市公司进行了调研，相关名单如下：1)百济神州调研纪要：公司在2025年实现净利润和正向自由现金流，经营活动净现金达11亿美元，自由现金流为正。这些考虑是上海景林做投资决定和估值过程中的核心。上海景林所管理的基金均给投资人创造了丰厚的长期回报。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303082402a69ac076&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303082402a69ac076&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4526","BK4588","BK4139","ONC","06160"],"gpt_icon":0},{"id":"2616680629","title":"业绩快报密集披露 电子及医药生物行业“领跑”","url":"https://stock-news.laohu8.com/highlight/detail?id=2616680629","media":"中国经济新闻网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616680629?lang=zh_cn&edition=fundamental","pubTime":"2026-03-02 10:40","pubTimestamp":1772419236,"startTime":"0","endTime":"0","summary":"A股2025年度业绩快报密集披露中。行业方面，净利润增长幅度居前的公司多集中在电子及医药生物行业。数据显示，从归母净利润增速来看，共有40家上市公司净利润同比增长幅度超过100%，电子及医药生物行业上市公司占据主导地位。同属医药生物行业的上海谊众2025年也取得不错业绩。根据业绩快报，上海谊众2025年度实现营业收入3.17亿元，同比增长82.72%；归属于母公司所有者的净利润6413.20万元，同比增长819.42%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302104626a72f8ac5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302104626a72f8ac5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","688235","BK1610","600030","00981","688108","688213","688981","BK1163","03866","688091","06030","CIIHY","BK1614","BK1526","ONC","BK1607","688041"],"gpt_icon":1}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":135,"code":"91000000","status":"200"}]}}